65 results
6-K
EX-99.1
SLN
Silence Therapeutics Plc
24 Jun 24
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
8:38am
contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release … or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation
6-K
EX-99.1
SLN
Silence Therapeutics Plc
20 Jun 24
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2
8:41am
the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward … environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause
6-K
EX-99.1
SLN
Silence Therapeutics Plc
16 May 24
Current report (foreign)
2:21pm
the Company settled outstanding patent litigation with Alnylam related to its RNAi product ONPATTRO. As part of the settlement, the Company licenses specified … into a settlement and license agreement with Alnylam, pursuant to which the Company settled outstanding patent litigation with Alnylam related to its RNAi
6-K
EX-99.1
SLN
Silence Therapeutics Plc
13 Mar 24
Current report (foreign)
7:10am
of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company’s cash runway and forecast
6-K
EX-99.1
668l9xhj9lto0 48c
23 Feb 24
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca
8:12am
6-K
EX-99.2
27izm1txa 6d5vjvut7
6 Feb 24
Securities Purchase Agreement
12:00am
6-K
EX-99.1
9088qwc4
6 Feb 24
Securities Purchase Agreement
12:00am
6-K
EX-99.1
5sum 4f3o07x1dok
1 Dec 23
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
7:00am
6-K
EX-99.1
rsgj dwjpzd4o
14 Nov 23
Current report (foreign)
12:00am
6-K
EX-99.1
ahwmw ek9bb8ftp
1 Nov 23
Current report (foreign)
7:00am
6-K/A
EX-99.1
byfdxhl1864t7u5
29 Aug 23
Current report (foreign) (amended)
4:01pm
6-K
EX-99.1
pengp hll4hsa
16 Aug 23
Current report (foreign)
7:00am
6-K
EX-99.1
f99c0lvw2wnet
11 Jul 23
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
7:00am
6-K
EX-99.1
e413szxf 9adcbbhu
16 May 23
Current report (foreign)
4:01pm
6-K
EX-99.1
3uhyl35bmij8ucussyq
4 May 23
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
7:41am
6-K
EX-99.1
1afe oofy
1 May 23
Current report (foreign)
7:31am
6-K
EX-99.1
zeczk6779kmpsbiu
10 Nov 22
Current report (foreign)
8:30am
6-K
EX-99.1
aj3oa
7 Nov 22
Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period
8:30am
6-K
EX-99.1
x1aaq65rc06
29 Sep 22
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
8:00am